Precision antibacterials to destroy antimicrobial-resistant bacteria in oncology
Pylum Biosciences has built a technology platform to create antibacterials that target individual strains of bacteria without affecting the microbiota. Its lead preclinical programs target Clostridioides difficile for infectious disease and Fusobacterium nucleatum for colorectal cancer.